Lenos, K., Grawenda, A., Lodder, K., Kuijjer, M., Teunisse, A., Repapi, E., . . . Jochemsen, A. (2012). Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Chicago Style (17th ed.) CitationLenos, K., et al. Alternate Splicing of the P53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than P53 Mutation in Human Cancer. 2012.
MLA (9th ed.) CitationLenos, K., et al. Alternate Splicing of the P53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than P53 Mutation in Human Cancer. 2012.
Warning: These citations may not always be 100% accurate.